Nanoparticle Albumin-Bound Paclitaxel in Oncology

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a solvent-free formulation in which paclitaxel is bound to human serum albumin nanoparticles. This design exploits endogenous albumin transport pathways—principally gp60-mediated transcytosis and stromal binding via the secreted protein acidic and rich in cysteine (SPARC)—to enhance intratumoural delivery and minimise solvent-related toxicities. Compared with conventional Cremophor EL-based paclitaxel, nab-paclitaxel permits higher dosing intensity, shorter infusion times and a markedly reduced incidence of hypersensitivity reactions. Clinically, it has gained approval in metastatic breast cancer, non-small-cell lung cancer and pancreatic adenocarcinoma, where it demonstrates improved tumour penetration, higher overall response rates and prolonged progression-free survival, with a tolerable safety profile. Research continues to explore predictive biomarkers of response, optimise combination regimens with immunotherapy and extend its utility into rarer malignancies such as sarcomas.

Research from Nature Portfolio

Recent meta-analyses encompassing over 1,500 patients with metastatic breast cancer have confirmed that nab-paclitaxel yields superior overall response and disease control rates compared with solvent-based taxanes, with significant gains in progression-free and overall survival and no substantial increase in severe adverse events. In non-small-cell lung cancer, a retrospective comparison of first-line nab-paclitaxel–cisplatin versus docetaxel–cisplatin demonstrated a markedly higher overall response rate and disease control rate, particularly in tumours of squamous histology, accompanied by reduced neutropenia and a favourable trend in survival outcomes. These findings reinforce the clinical advantage of albumin-bound delivery in diverse histological subtypes.

Nanoparticle Albumin-Bound Paclitaxel in Oncology publication trend

The graph below shows the total number of articles in nanoparticle albumin-bound paclitaxel in oncology across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): A formulation of the chemotherapeutic agent paclitaxel bound to albumin nanoparticles to enhance tumour uptake and reduce solvent toxicity.

Overall response rate (ORR): The proportion of patients achieving a predefined reduction in tumour size.

Disease control rate (DCR): The proportion of patients who achieve complete response, partial response or stable disease.

Progression-free survival (PFS): The interval from treatment initiation to disease progression or death from any cause.

Pharmacokinetics (PK): The study of drug absorption, distribution, metabolism and excretion.

Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs and their mechanisms of action.

RECIST criteria: A standardised set of guidelines for assessing tumour response based on imaging measurements.

References

1. Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Acta Materia Medica (2023).
2. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology (2015).
3. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. Scientific Reports (2020).
4. Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer. Scientific Reports (2017).
5. Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas. Frontiers in Oncology (2022).